GlassScriptPhysician profile
Abdul Bhutta
NPI 1417268566
$6,137.09
in general payments reported to CMS, 2019-2025
32 companies · $3,297 in 2025
The $3,297 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $100 · 2023: $937 · 2024: $1,803 · 2025: $3,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,023 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,023.19 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.17 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Intra-Sana Laboratories | $766.20 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Biotech, INC. | $409.05 | 2023-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $344.58 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.41 | 2023-2025 | Xifaxan, Plenvu, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $322.53 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Medtronic, INC. | $255.59 | 2025 | Interstim |
| Axonics, INC. | $255.06 | 2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $253.20 | 2022-2025 | Linzess |
| Janssen Scientific Affairs, LLC | $213.51 | 2024-2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $187.29 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $183.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $165.53 | 2024-2025 | |
| Sanofi US Services INC. | $130.93 | 2025 | |
| Celltrion USA INC. | $114.68 | 2025 | Vegzelma |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $99.51 | 2023-2024 | Idacio |
| Novo Nordisk INC | $94.39 | 2025 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $89.27 | 2023-2025 | Dupixent |
| Myriad Women'S Health, INC. | $86.09 | 2023 | Myrisk |
| Intercept Pharmaceuticals, INC. | $84.74 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $76.70 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $69.50 | 2023 | |
| Aimmune Therapeutics, INC. | $47.98 | 2024 | |
| Alnylam Pharmaceuticals INC. | $41.00 | 2025 | Givlaari |
| Lilly USA, LLC | $39.08 | 2024 | Omvoh, Zepbound |
| Pfizer INC. | $37.27 | 2025 | |
| Ferring Pharmaceuticals INC. | $37.18 | 2024-2025 | Clenpiq, Rebyota |
| Blueprint Medicines Corporation | $36.52 | 2025 | Ayvakit |
| Sandoz INC. | $34.57 | 2024 | Hyrimoz |
| Redhill Biopharma INC. | $31.95 | 2023-2024 | Aemcolo, Talicia |
| Mallinckrodt Hospital Products INC. | $21.37 | 2024 | Terlivaz |
| Celgene Corporation | $18.50 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Bhutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.